Biohaven Ltd.

Biohaven Ltd.

BHVN·NYSE

$11.35

+12%
HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

At a Glance

Live Snapshot
Market Cap$1.20B
EPS-6.8600
P/E Ratio-1.65
Earnings Date08/10/2026

bhvn

Account Payables

Last Annual Value

11.64M

3-Year CAGR

3%

5-Year CAGR

33%

10-Year CAGR

9%

Biohaven Ltd.

Biohaven Ltd. Competitors Analysis of Account Payables

BHVN · NYSE
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
BHVN logo
Biohaven Ltd.
NYSE:BHVN
11.64M
-9.2%19.5%N/A 
20.25M
39.6%16.0%15.8%
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
3.34M
0.3%1.6%N/A
21.90M
25.4%73.7%N/A
769.00K
2.3%N/AN/A
7.11M
9.6%N/AN/A
3.08M
-35.7%-19.2%8.9%
1.18M
-30.4%-0.8%-3.8%
Biohaven Ltd.

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.35, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

Intrinsic Value
Current Price: $11.35